Atrial natriuretic peptide gene transfer by means of intranasal administration attenuates airway reactivity in a mouse model of allergic sensitization.
Atrial natriuretic peptide (ANP) is a bronchodilator; however, the short half-life of ANP in vivo limited its therapeutic utility to treat asthma. The efficacy of intranasally administered plasmid DNA-expressing ANP (pANP; amino acid 99-126; Acc. No. XM131840) on the prevention of allergen-induced airway hyperresponsiveness (AHR) was examined in this study by using a mouse model of asthma. Ovalbumin-sensitized mice were treated with pANP versus control plasmids, and AHR was monitored after ovalbumin challenge for 5 weeks on 10-day intervals starting 4 days after gene transfer. Mice administered pANP demonstrated significantly less AHR for 20 days after treatment. The results demonstrate that pANP gene transfer protects against AHR and might be useful in the treatment of asthma.
Kumar
Mukesh
M
Division of Allergy and Immunology-Joy McCann Culverhouse Airway Disease Center, University of South Florida College of Medicine and James A. Haley Veteran's Hospital, Tampa 33612, USA.
Behera
Aruna K
AK
Lockey
Richard F
RF
Vesely
David L
DL
Mohapatra
Shyam S
SS
D000281:Administration, Intranasal; D000818:Animals; D001249:Asthma / Q000628:therapy*; D009320:Atrial Natriuretic Factor / Q000235:genetics*; D016535:Bronchial Hyperreactivity / Q000517:prevention & control*; D004195:Disease Models, Animal; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D008168:Lung / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000276:immunology
D009320:Atrial Natriuretic Factor; D010047:Ovalbumin